A federal appeals court has significantly limited reproductive healthcare access nationwide by prohibiting the postal delivery of mifepristone, a medication commonly used for abortion procedures.
The court decision impacts what has become one of the most frequently used methods for terminating pregnancies in the United States. The ruling prevents the medication from being sent through the mail system, creating new barriers for patients seeking abortion care.
Mifepristone is widely prescribed as part of a two-drug regimen for medication abortions, which account for a substantial portion of abortion procedures performed across the country.
